🔎 Trials Near Me

Home › Coronary Artery Disease › Pennsylvania

Coronary Artery Disease clinical trials in Pennsylvania

15 studies for Coronary Artery Disease are looking for participants at sites in Pennsylvania.

Cities in Pennsylvania

Pivotal Study of the SUpira System in Patients Undergoing High-Risk Percutaneous COronaRy InTervention (HRPCI)

  • University of Pennsylvania, Philadelphia
  • Wellspan York Hospital, York
Recruiting
Ages 18 to 90 · All sexes · Updated Sep 30, 2026 · NCT07296744

Inclisiran Versus Placebo for the Prevention of Major Adverse Cardiovascular and Limb Events in Patients Undergoing Percutaneous Coronary Intervention or Peripheral Endovascular Intervention

  • St. Luke's University Health Network, Bethlehem
  • Capital Area Research LLC, Camp Hill
  • Wellspan Chambersburg Hospital, Chambersburg
  • and 3 more
RecruitingPhase 4
Ages 18 and older · All sexes · Updated Sep 28, 2026 · NCT06909565

A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis

  • Capital Area Research, LLC - Camp Hill, Camp Hill
RecruitingPhase 2
Ages 18 to 80 · All sexes · Updated Sep 22, 2026 · NCT07521007

Combined Dose-Finding and CV Outcomes Study With CSL300 (Clazakizumab) in Adult Subjects With ESKD Undergoing Dialysis (POSIBIL6ESKD)

  • Northeast Clinical Research Center, LLC, Bethlehem
  • Clinical Renal Associates, LTD, Exton
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Sep 21, 2026 · NCT05485961

Product Surveillance Registry

  • Allentown
  • Bethlehem
  • Danville
  • and 6 more
RecruitingObservational study
All ages · All sexes · Updated Sep 18, 2026 · NCT01524276

Investigational Trial to Evaluate XC001 Delivered Via an Cardiac Catheter in Subjects With Chronic Angina.

  • Lehigh Valley Health Network, Allentown
RecruitingPhase 2
Ages 18 to 85 · All sexes · Updated Sep 11, 2026 · NCT07048808

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

  • Clinical Study Center, Philadelphia
RecruitingPhase 1
Ages 18 to 70 · All sexes · Updated Sep 2, 2026 · NCT06164730

Randomization of Single vs Multiple Arterial Grafts

  • Allegheny General Hospital (Cardiovascular Institute), Pittsburgh
Recruiting
Ages 18 to 70 · All sexes · Updated Aug 20, 2026 · NCT03217006

Prospective Global Registry for the Study of Chronic Total Occlusion Intervention

  • University of Pittsburgh Medical Center Presbyterian, Pittsburgh
  • WellSpan Heart & Vascular, York
RecruitingObservational study
All ages · All sexes · Updated Aug 19, 2026 · NCT02061436

Virtue® SAB in the Treatment of Coronary ISR Trial

  • Thomas Jefferson University, Philadelphia
  • WellSpan Health, York
Recruiting
Ages 18 and older · All sexes · Updated Jul 23, 2026 · NCT07045194

Prevail Global Study

  • Lehigh Valley Hospital - Cedar Crest, Allentown
  • UPMC Pinnacle Harrisburg Campus, Harrisburg
  • Hospital of the University of Pennsylvania, Philadelphia
Recruiting
Ages 18 and older · All sexes · Updated Apr 24, 2026 · NCT06535854

Comparison of the Outcomes of Single vs Multiple Arterial Grafts in Women

  • University of Pennsylvania, Philadelphia
  • Allegheny General Hospital, Pittsburgh
  • Lankenau Medical Center, Wynnewood
Recruiting
Ages 18 and older · Women · Updated Apr 1, 2026 · NCT04124120

Remote Ischemic Preconditioning for Renal and Cardiac Protection in Congestive Heart Failure (RICH) Trial

  • VA Pittsburgh Healthcare System University Drive Division, Pittsburgh, PA, Pittsburgh
RecruitingPhase 2/3
Ages 18 and older · All sexes · Updated Dec 15, 2025 · NCT04982419

MagicTouch™Sirolimus-Coated Balloon for Treatment of Coronary Artery Lesions in Small Vessels

  • University of Pittsburgh Medical center (UPMC), Pittsburgh
Recruiting
Ages 18 to 80 · All sexes · Updated Sep 11, 2025 · NCT06271590

PIvotal Trial of the KARDION Cory P4 MechANical Circulatory SupporT SystEm

  • Heart and Vascular Research at WellSpan Health, York
Recruiting
Ages 18 to 90 · All sexes · Updated Jun 13, 2025 · NCT06445608

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.